Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Dichloroacetate · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Dichloroacetate | DRUG | Continuous daily oral dosage (bid). |
Inclusion Criteria: 1. Patients must have histologically or cytologically confirmed recurrent or metastatic solid tumours. All patients will have no meaningful therapies available to them including hormone therapy, chemotherapy and targeted therapies. For the malignancies that have no proven therap...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
Dichloroacetate is an investigational small molecule being studied for the treatment of neoplasms, specifically recurrent and/or metastatic solid tumors. It is currently in Phase 1 clinical development as a potential oncology therapy.
Dichloroacetate is a small molecule that targets metabolic pathways in cancer cells. It works by inhibiting pyruvate dehydrogenase kinase, which shifts cellular metabolism from glycolysis to oxidative phosphorylation, potentially reducing tumor growth.
Dichloroacetate is being developed by Avalon GloboCare Corp., a biopharmaceutical company. The company's stock is traded under the ticker symbol ALBT.
Dichloroacetate is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
Dichloroacetate has one completed clinical trial, NCT00566410, a Phase 1 open-label, single-arm, dose escalation study in patients with recurrent and/or metastatic solid tumors. The trial enrolled 23 participants in Canada.
Yes, Dichloroacetate is commonly referred to as DCA. It is a small molecule being investigated for its potential anti-cancer effects in solid tumors.